NL-GHK-Cu in reducing pain and inflammation in the body

Therapy with the NL-GHK-Cu peptide allows the restoration of comfort in daily functioning through the elimination of pain and inflammatory conditions in the body. Additionally, it is a modern peptide therapy that significantly reduces the occurrence of the aforementioned conditions.

Introduction

According to the definition, pain is a negative and unpleasant sensory and emotional experience associated with actual or potential tissue damage. Inflammation is, in turn, a defensive response of the body to tissue-damaging stimuli. The purpose of inflammation is to create conditions for the repair and regeneration of damaged tissues. Both of these conditions—pain and inflammation—lead to a deterioration in daily functioning and quality of life. The mechanisms of pain and inflammation are complex and require proper therapeutic management. If treated improperly, they may lead to many unpleasant consequences. According to research, the NL-GHK-Cu peptide is used in pain therapy by reducing serotonin release and eliminating inflammation through the reduction of pro-inflammatory cytokine production, as a modern peptide-based therapy.

PAIN

Pain is an unpleasant sensory and emotional experience associated with actual, ongoing, or potential tissue damage. Pain most often results from stimulation of receptors, specifically pain receptors—nociceptors—or from a lowered threshold of receptor excitability. The primary function of pain is its protective and warning role, alerting the body to potential tissue damage caused by injury or disease, triggering a response aimed at minimizing the effects of such damage.

Pain forces a reduction in physical activity, which in this context is beneficial, as increased tissue sensitivity helps prevent further damage. In most cases, properly managed acute pain resolves within a short period ranging from a few hours to several days. Improper pain management may lead to progressive pathophysiological changes in the central nervous system (CNS), transforming acute pain into chronic pain. Therefore, appropriate and effective treatment at the earliest stage of symptoms is crucial.

PAIN PATHOMECHANISM

• Acute pain

The concept of nociception refers to the process of pain generation, which includes four stages: transduction, transmission, modulation, and perception. In the first stage—transduction—the energy of a damaging stimulus (mechanical, thermal, or chemical) is converted into an electrical impulse conducted by nerve fibers at the peripheral endings of the nociceptive neuron. Tissue damage leads to the release of bradykinin, serotonin, and substance P, responsible for neurogenic inflammation at the injury site, manifested by pain, redness, and swelling. The encoded electrical signal is transmitted during the conduction phase to the dorsal root ganglia of spinal nerves, where excitatory amino acids, substance P, and neurokinin A are released and transmitted to synapses formed by central endings of nociceptive neurons in the dorsal horn of the spinal cord. From the dorsal horn, nociceptive information is transmitted to higher levels of the CNS. The final stage of nociception is perception in the brain, responsible for awareness of pain stimuli, their evaluation, and emotional and affective responses such as fear, aggression, and anger, as well as the formation of pain-related behavioral patterns.

• Chronic pain

Chronic pain refers to pain experienced over a long period of time, typically lasting longer than 3 months or persisting despite tissue healing. It is increasingly considered a disease in itself requiring specialized therapeutic management. Patients suffering from chronic pain experience reduced quality of life, including physical, psychological, and social dysfunctions. The severity depends on the duration and intensity of pain rather than its original cause.

PAIN LOCALIZATION

Localized pain

As the name suggests, localized pain is confined to a specific area of the body, such as abdominal pain or toothache.

Referred pain

Referred pain is a type of transferred pain, most often radiating from internal organs to the skin, as each internal organ corresponds to a dermatomal region. It is not a separate disease entity but a symptom of another condition. It often occurs in the cervical, thoracic, and lumbar spine regions.

Generalized pain

This type of pain is mainly associated with damage to the somatic nervous system and is not linked to specific receptors in a given body region.

Multisite pain

Pain occurring in ≥4 of 5 body regions, excluding the jaw, chest, and abdomen.

INFLAMMATORY RESPONSE OF THE BODY

Inflammation is a defensive response of the body to harmful factors. It involves immune cells, connective tissue cells, certain blood proteins, and blood vessels. The purpose of inflammation is to eliminate the harmful agent, neutralize it, and repair damaged tissues.

COURSE OF THE INFLAMMATORY RESPONSE

Heat, redness, and swelling of the inflamed area are the direct result of vascular reactions to tissue damage. This begins with a brief vasoconstriction followed by prolonged vasodilation. Increased capillary permeability leads to fluid leakage into surrounding tissues and edema formation. Subsequently, immune cells migrate to the site of injury forming an inflammatory infiltrate. The first cells to arrive are neutrophils, followed by eosinophils (in allergic reactions), lymphocytes, and macrophages (in chronic inflammation). Leukocyte migration is mediated by adhesion molecules on endothelial and immune cells.

ANALGESIC EFFECT OF NL-GHK-Cu

Studies have shown that the NL-GHK-Cu peptide exhibits analgesic effects. In particular, its L-lysine component plays a key role in pain modulation. The peptide regulates peptidase activity and promotes tissue-specific processing products. It has also been shown to reduce serotonin secretion, which is involved in neurogenic inflammation and pain development at injury sites.

ANTI-INFLAMMATORY EFFECT OF NL-GHK-Cu

The NL-GHK-Cu complex has been shown to inhibit inflammatory and fibrotic changes, reduce inflammatory responses by lowering pro-inflammatory cytokines TNF-α and IL-6, and reducing MPO (myeloperoxidase) activity. Additionally, NL-GHK-Cu reverses the MMP-9/TIMP-1 imbalance and partially prevents EMT (epithelial-mesenchymal transition) via Nrf2, NF-κB, and TGFβ1 pathways, as well as Smad2/3 phosphorylation.

BIBLIOGRAPHY

1. Wordliczek J, Dobrogowski J. Pain Treatment. 2007; 11–27:2

2. Wordliczek J, Dobrogowski J. Pain Medicine. 2004; 17–39

3. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. 2017; 19(7):1987. doi:10.3390/ijms19071987

4. Sever'yanova L, Dolgintsev M. Effects of Tripeptide Gly-His-Lys in Pain-Induced Aggressive-Defensive Behavior in Rats. 2017; 164(2):140–143. doi:10.1007/s10517-017-3943-3

5. Wen-Hui M, Meng L, Hai-Feng M, Wei L, Li L, Yan Y, Xiao-Ming Z, Gang H. Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammatory pathways. 2019; 15;241:117139. doi:10.1016/j.lfs.2019.117139